Point72 Asset Management L.P. purchased a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) during the second quarter, Holdings Channel reports. The firm purchased 470,247 shares of the company’s stock, valued at approximately $6,480,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Braidwell LP boosted its position in shares of Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of Day One Biopharmaceuticals by 65.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after buying an additional 1,157,825 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after buying an additional 472,654 shares in the last quarter. Janus Henderson Group PLC grew its position in Day One Biopharmaceuticals by 19.8% in the first quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock valued at $33,575,000 after acquiring an additional 336,281 shares during the last quarter. Finally, Estuary Capital Management LP raised its stake in Day One Biopharmaceuticals by 82.5% during the first quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock worth $26,616,000 after acquiring an additional 728,240 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.
Insider Buying and Selling at Day One Biopharmaceuticals
In other news, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares of the company’s stock, valued at approximately $376,992. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total value of $320,200.00. Following the completion of the sale, the insider now directly owns 1,121,081 shares in the company, valued at $17,948,506.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,748 shares of company stock valued at $1,009,272. 8.40% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on DAWN
Day One Biopharmaceuticals Trading Up 0.5 %
NASDAQ DAWN opened at $14.00 on Wednesday. Day One Biopharmaceuticals, Inc. has a 12 month low of $9.67 and a 12 month high of $18.07. The firm has a market capitalization of $1.22 billion, a PE ratio of -5.58 and a beta of -1.51. The business’s 50-day moving average price is $14.08 and its two-hundred day moving average price is $14.48.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.70. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. As a group, analysts forecast that Day One Biopharmaceuticals, Inc. will post -1.68 earnings per share for the current fiscal year.
Day One Biopharmaceuticals Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
- Five stocks we like better than Day One Biopharmaceuticals
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Stock Market Sectors: What Are They and How Many Are There?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- The 3 Best Retail Stocks to Shop for in August
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding DAWN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report).
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.